human | Q5 |
P496 | ORCID iD | 0000-0002-4226-6435 |
P27 | country of citizenship | Canada | Q16 |
P108 | employer | University of Toronto | Q180865 |
P735 | given name | Irene | Q389528 |
Irene | Q389528 | ||
P106 | occupation | researcher | Q1650915 |
P21 | sex or gender | female | Q6581072 |
Q64115284 | 10-year performance of four models of breast cancer risk: a validation study |
Q36016386 | 11q13 is a susceptibility locus for hormone receptor positive breast cancer |
Q35871567 | 19p13.1 is a triple-negative-specific breast cancer susceptibility locus |
Q33848895 | 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy |
Q37169873 | 9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium |
Q36029709 | A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma |
Q59355837 | A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk |
Q35957063 | A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density |
Q37272982 | A genome wide linkage search for breast cancer susceptibility genes |
Q29417036 | A genome-wide association study of early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for breast cancer at any age. |
Q35889669 | A genome-wide linkage study of mammographic density, a risk factor for breast cancer |
Q36577115 | A high-resolution copy-number variation resource for clinical and population genetics |
Q37619303 | A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium |
Q35089479 | A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population |
Q34521165 | A mutant PTH/PTHrP type I receptor in enchondromatosis |
Q92711687 | A network analysis to identify mediators of germline-driven differences in breast cancer prognosis |
Q36152991 | A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers |
Q81234958 | A pilot genome-wide association study of early-onset breast cancer |
Q39982410 | A qualitative study evaluating parental attitudes towards the creation of a female youth cohort (LEGACY) in the Breast Cancer Family Registry |
Q35063910 | A role for asparaginyl-tRNA in the regulation of asparagine synthetase in a mammalian cell line |
Q30489618 | A role for the TGFbeta-Par6 polarity pathway in breast cancer progression |
Q57305942 | A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer |
Q36043159 | ABRAXAS (FAM175A) and Breast Cancer Susceptibility: No Evidence of Association in the Breast Cancer Family Registry |
Q37417780 | AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study |
Q37700795 | Aberrant hedgehog signaling and clinical outcome in osteosarcoma |
Q37218002 | Aberrant methylation of RASSF1A in plasma DNA before breast cancer diagnosis in the Breast Cancer Family Registry |
Q114612672 | Abstract 1395: Identification of genes and pathways related to lymphovascular invasion in axillary-node negative breast cancer: A bioinformatic analysis of gene expression data |
Q58074718 | Abstract 4593: Genome-wide association study identifies novel loci associated with osteosarcoma |
Q58074642 | Abstract 5574: High prevalence of germline TP53 mutations in young osteosarcoma cases |
Q92102602 | Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management Tool |
Q36497745 | Accuracy of Self-Reported Breast Cancer Information among Women from the Ontario Site of the Breast Cancer Family Registry |
Q37105163 | Accuracy of Self-Reported Screening Mammography Use: Examining Recall among Female Relatives from the Ontario Site of the Breast Cancer Family Registry |
Q35231571 | Adherence to breast and ovarian cancer screening recommendations for female relatives from the Ontario site of the Breast Cancer Family Registry |
Q39437211 | Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers |
Q58613780 | Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC) |
Q91618412 | Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium |
Q91518331 | Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the Prospective Family Study Cohort (ProF-SC) |
Q79703376 | Alcohol metabolism, alcohol intake, and breast cancer risk: a sister-set analysis using the Breast Cancer Family Registry |
Q28299137 | Altered expression and deletion of RMO1 in osteosarcoma |
Q48485483 | Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors. |
Q51024001 | Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. |
Q36073563 | An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression |
Q46063050 | An inverse association between ovarian cysts and breast cancer in the breast cancer family registry |
Q35618307 | An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers |
Q68184562 | Analysis of alterations in the retinoblastoma gene and tumor grade in bone and soft-tissue sarcomas |
Q24170413 | Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types |
Q35605807 | Analysis of incidence and prognostic factors for ipsilateral breast tumour recurrence and its impact on disease-specific survival of women with node-negative breast cancer: a prospective cohort study |
Q35753119 | Analysis of mRNA from microdissected frozen tissue sections without RNA isolation |
Q33229208 | Application of reliability coefficients in cDNA microarray data analysis |
Q39282400 | Asparaginyl-tRNA aminoacylation levels and asparagine synthetase expression in cultured Chinese hamster ovary cells |
Q35242849 | Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers |
Q34613673 | Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study |
Q64940233 | Assessing patient readiness for personalized genomic medicine. |
Q57937919 | Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival |
Q35218520 | Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy |
Q45979098 | Association analysis identifies 65 new breast cancer risk loci. |
Q27851709 | Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer |
Q91271723 | Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness |
Q36072765 | Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study |
Q64112402 | Association of Prepubertal and Adolescent Androgen Concentrations With Timing of Breast Development and Family History of Breast Cancer |
Q36178189 | Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. |
Q37684672 | Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. |
Q37268494 | Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry |
Q114182713 | Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment |
Q99609984 | Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer |
Q46121002 | Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers |
Q34801008 | Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
Q35957703 | Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer |
Q119213340 | Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival |
Q35022847 | Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies |
Q35523236 | Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers |
Q35532898 | Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium |
Q57056093 | Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis |
Q35416040 | Atypical protein kinase C zeta: potential player in cell survival and cell migration of ovarian cancer |
Q92904333 | Authors' response: Associations of obesity and circulating insulin and glucose with breast cancer risk |
Q64039257 | BRCA1 and BRCA2 Pathogenic Sequence Variants in Women of African Origin or Ancestry |
Q37416050 | BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research |
Q34571646 | BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. |
Q36621949 | BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients |
Q74449532 | BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in non-familial cases |
Q38914005 | BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer |
Q37002955 | BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers |
Q42506232 | BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays |
Q34334167 | Beliefs about optimal age and screening frequency predict breast screening adherence in a prospective study of female relatives from the Ontario site of the Breast Cancer Family Registry |
Q91375393 | Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort |
Q42802070 | Biochemical characterization of a mutant asparaginyl-tRNA synthetase from Chinese hamster ovary cells |
Q35599920 | Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. |
Q46036353 | Biomarker significance of plasma and tumor miR-21, miR-221, and miR-106a in osteosarcoma. |
Q46115524 | Body mass index and breast cancer survival: a Mendelian randomization analysis |
Q50046604 | Breast Cancer Family History and Allele-Specific DNA Methylation in the Legacy Girls Study. |
Q100457582 | Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk |
Q57265621 | Breast Cancer Prognosis inBRCA1andBRCA2Mutation Carriers: An International Prospective Breast Cancer Family Registry Population-Based Cohort Study |
Q114182645 | Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores |
Q34327945 | Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2 |
Q35609710 | Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry |
Q37410693 | Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab |
Q35940158 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. |
Q33767889 | Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different? |
Q57305977 | Breast-Cancer Risk in Families With Mutations in PALB2 |
Q34148873 | Breast-cancer risk in families with mutations in PALB2 |
Q41667015 | CD10 and CD44 genes of leukemic cells and malignant cell lines show no evidence of transformation-related alterations |
Q36449203 | CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer |
Q35050626 | CK8/18 expression, the basal phenotype, and family history in identifying BRCA1-associated breast cancer in the Ontario site of the breast cancer family registry |
Q79967598 | COPS3 amplification and clinical outcome in osteosarcoma |
Q92005489 | Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families |
Q114657791 | Cancer Risks Associated With and Pathogenic Variants |
Q34963894 | Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
Q24329205 | Cell cycle regulated phosphorylation of LIMD1 in cell lines and expression in human breast cancers |
Q38421601 | Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. |
Q44173416 | Characteristics associated with participation at various stages at the Ontario site of the cooperative family registry for breast cancer studies |
Q43742885 | Characterization of single step albizziin-resistant Chinese hamster ovary cell lines with elevated levels of asparagine synthetase activity |
Q45065658 | Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma |
Q96962174 | Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) |
Q36937122 | Chromosomal Alterations Associated with Overproduction of Asparagine Synthetase in Albizziin-Resistant Chinese Hamster Ovary Cells |
Q36997687 | Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers |
Q79269372 | Cloning and mutation analysis of ZFP276 as a candidate tumor suppressor in breast cancer |
Q34492917 | Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas |
Q37219731 | Cohort Profile: The Breast Cancer Prospective Family Study Cohort (ProF-SC) |
Q94486442 | Combined associations of a polygenic risk score and classical risk factors with breast cancer risk |
Q33314644 | Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk |
Q37368000 | Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms |
Q101133507 | Common Childhood Viruses and Pubertal Timing: The LEGACY Girls Study |
Q36839777 | Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers |
Q34394665 | Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction |
Q35889575 | Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. |
Q36600605 | Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk |
Q24655824 | Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers |
Q33742096 | Common genetic variants and modification of penetrance of BRCA2-associated breast cancer |
Q35794653 | Common germline polymorphisms associated with breast cancer-specific survival |
Q34379032 | Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium |
Q36393232 | Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers |
Q35870067 | Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
Q37434133 | Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers |
Q115209587 | Common variants in breast cancer risk loci predispose to distinct tumor subtypes |
Q34213403 | Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers |
Q104263819 | Comparing Five-Year and Lifetime Risks of Breast Cancer in the Prospective Family Study Cohort |
Q31082788 | Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
Q37047463 | Comparison of Clinical, Maternal, and Self Pubertal Assessments: Implications for Health Studies |
Q40718941 | Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations |
Q52579925 | Comparison of methods to assess onset of breast development in the LEGACY Girls Study: methodological considerations for studies of breast cancer. |
Q74610152 | Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma |
Q34181322 | Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer |
Q90481059 | Considerations when using breast cancer risk models for women with negative BRCA1/BRCA2 mutation results |
Q35070800 | Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation |
Q35029565 | Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry |
Q89897900 | Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers |
Q57266620 | Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer |
Q45793899 | Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer. |
Q57278898 | Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
Q91090014 | Correction: Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers |
Q34084261 | Correlation of DNA methylation levels in blood and saliva DNA in young girls of the LEGACY Girls study |
Q41365367 | Correlation of p-glycoprotein detection by immunohistochemistry with mdr-1 mRNA levels in osteosarcomas. Pilot study |
Q21144874 | DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers |
Q36769488 | DNA methylation patterns associated with asparagine synthetase expression in asparagine-overproducing and -auxotrophic cells |
Q37685729 | DNA mismatch repair gene MSH6 implicated in determining age at natural menopause |
Q71814442 | Detailed deletion mapping with a refined physical map of 7q31 localizes a putative tumor suppressor gene for breast cancer in the region of MET |
Q23916196 | Detectable clonal mosaicism and its relationship to aging and cancer |
Q80153079 | Detection and typing of human papillomavirus in verrucous carcinoma of the oral cavity using the polymerase chain reaction |
Q33588213 | Diagnostic chest X-rays and breast cancer risk before age 50 years for BRCA1 and BRCA2 mutation carriers |
Q38927282 | Dietary isoflavone intake and all-cause mortality in breast cancer survivors: The Breast Cancer Family Registry |
Q43591191 | Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information |
Q35049656 | Does perceived risk predict breast cancer screening use? Findings from a prospective cohort study of female relatives from the Ontario site of the breast cancer family registry |
Q38444030 | E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma in situ of the breast |
Q37843728 | EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry |
Q87374141 | ERβ splice variant expression in four large cohorts of human breast cancer patient tumors |
Q54158232 | EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. |
Q27851507 | EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma |
Q42518726 | Elevated expression of podocalyxin is associated with lymphatic invasion, basal-like phenotype, and clinical outcome in axillary lymph node-negative breast cancer |
Q28288212 | Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis |
Q46576086 | Erratum to: Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors |
Q93484362 | Erratum to: PATCHED-ONE or SMOOTHENED Gene Mutations Are Infrequent in Chondrosarcoma |
Q47331743 | Ethnicity, but not cancer family history, is related to response to a population-based mailed questionnaire |
Q33614244 | Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers |
Q37481884 | Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). |
Q91549968 | Evaluation of associations between genetically predicted circulating protein biomarkers and breast cancer risk |
Q36352389 | Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers |
Q37745041 | Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers |
Q33894527 | Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium |
Q35653910 | Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk |
Q36720821 | Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors |
Q35064451 | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation |
Q37342144 | Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation |
Q41004639 | Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma |
Q38318239 | Expression of osteocalcin and its transcriptional regulators core-binding factor alpha 1 and MSX2 in osteoid-forming tumours |
Q34708024 | Expression of the circadian clock genes Per1 and Per2 in sporadic and familial breast tumors |
Q54242131 | Expression of the multidrug resistance gene in osteosarcoma: a pilot study. |
Q41260882 | Expression of the multiple drug resistance gene in human renal cell carcinoma depends on tumor histology, grade, and stage. |
Q37306967 | Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors |
Q37594336 | FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium |
Q33967959 | Factors affecting distant disease-free survival for primary invasive breast cancer: use of a log-normal survival model |
Q24539146 | Familial posterior fossa brain tumors of infancy secondary to germline mutation of the hSNF5 gene |
Q37308563 | Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry |
Q45137915 | Family-based association study of IGF1 microsatellites and height, weight, and body mass index |
Q51811339 | Family-based genetic association study of insulin-like growth factor I microsatellite markers and premenopausal breast cancer risk. |
Q37236216 | Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). |
Q35158606 | Fine structure analysis of the Chinese hamster AS gene encoding asparagine synthetase |
Q36111237 | Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus |
Q36087170 | Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers |
Q35524465 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. |
Q61230414 | Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes |
Q92480972 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes |
Q39844032 | Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer |
Q36248936 | Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk |
Q34903062 | Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. |
Q37367871 | Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. |
Q44023983 | Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations |
Q88096707 | Fresh Cut Versus Stored Cut Paraffin-embedded Tissue: Effect on Immunohistochemical Staining for Common Breast Cancer Markers |
Q114182808 | Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element |
Q57419070 | Functional characterization of novel presenilin-2 variants identified in human breast cancers |
Q36124728 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus |
Q36742577 | Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers |
Q90824840 | Gene-based and pathway-based testing for rare-variant association in affected sib pairs |
Q35832873 | Gene-expression patterns in peripheral blood classify familial breast cancer susceptibility |
Q35999323 | Genetic determinants of telomere length and risk of common cancers: a Mendelian randomization study |
Q108609948 | Genetic insights into biological mechanisms governing human ovarian ageing |
Q37739048 | Genetic modifiers of CHEK2*1100delC-associated breast cancer risk |
Q29417068 | Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study |
Q35925620 | Genetic predisposition to ductal carcinoma in situ of the breast |
Q35151684 | Genetic predisposition to in situ and invasive lobular carcinoma of the breast |
Q52561250 | Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies. |
Q33811527 | Genetic variants associated with breast cancer risk for Ashkenazi Jewish women with strong family histories but no identifiable BRCA1/2 mutation |
Q44743159 | Genetic variants of GPX1 and SOD2 and breast cancer risk at the Ontario site of the Breast Cancer Family Registry |
Q35022825 | Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers |
Q35179897 | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study |
Q34378972 | Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade |
Q36422109 | Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium |
Q30000080 | Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent |
Q92387949 | Genetically Predicted Levels of DNA Methylation Biomarkers and Breast Cancer Risk: Data From 228 951 Women of European Descent |
Q37364660 | Genome wide screening of CAG trinucleotide repeat lengths in breast cancer |
Q36842233 | Genome-wide association analysis identifies three new breast cancer susceptibility loci |
Q35996692 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer |
Q63681757 | Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer |
Q24622610 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci |
Q95329367 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses |
Q46904091 | Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients |
Q28659642 | Genome-wide association study identifies two susceptibility loci for osteosarcoma |
Q27008356 | Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk |
Q64040390 | Genome-wide association study of germline variants and breast cancer-specific mortality |
Q38436572 | Genomic alterations in lobular neoplasia: a microarray comparative genomic hybridization signature for early neoplastic proliferationin the breast |
Q59566871 | Genomic analyses for age at menarche identify 389 independent signals and indicate BMI-independent effects of puberty timing on cancer susceptibility |
Q38823212 | Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk |
Q36465250 | Genomics and premalignant breast lesions: clues to the development and progression of lobular breast cancer |
Q44314670 | Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients |
Q96432094 | Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk |
Q36294747 | Germline TP53 variants and susceptibility to osteosarcoma. |
Q59756250 | Germline Variation and Breast Cancer Incidence: A Gene-Based Association Study and Whole-Genome Prediction of Early-Onset Breast Cancer |
Q35114576 | Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer |
Q34414768 | Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. |
Q34643959 | Global DNA methylation levels in girls with and without a family history of breast cancer |
Q44202163 | HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry |
Q54600960 | HER2 and responsiveness of breast cancer to adjuvant chemotherapy. |
Q80463670 | HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab |
Q35382206 | Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers |
Q57471595 | Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study |
Q36276540 | Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization |
Q71257737 | Heteroduplex and protein truncation analysis of the BRCA1 185delAG mutation |
Q43812884 | Histidyl-tRNA synthetase of Chinese hamster ovary cells contains phosphoserine |
Q41961367 | Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape |
Q34522623 | Human subjects protection: an event monitoring committee for research studies of girls from breast cancer families |
Q41698482 | Hypomethylation and reactivation of the asparagine synthetase gene induced by L-asparaginase and ethyl methanesulfonate |
Q35448920 | Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancer |
Q35102646 | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk |
Q30252854 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer |
Q36720814 | Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk |
Q39321320 | Identification of fifteen novel germline variants in the BRCA1 3'UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site |
Q36859142 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer |
Q35608709 | Identification of germline alterations of the mad homology 2 domain of SMAD3 and SMAD4 from the Ontario site of the breast cancer family registry (CFR) |
Q36086247 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus |
Q47161199 | Identification of new breast cancer predisposition genes via whole exome sequencing |
Q34038964 | Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions |
Q36014067 | Identification of novel genetic markers of breast cancer survival |
Q28250209 | Identification of rare variants in the hLIMD1 gene in breast cancer |
Q35541663 | Identification of six new susceptibility loci for invasive epithelial ovarian cancer |
Q46103372 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer |
Q48005435 | Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma. |
Q112712388 | Immuno-transcriptomic profiling of extracranial pediatric solid malignancies |
Q51196865 | Impact of familial risk and mammography screening on prognostic indicators of breast disease among women from the Ontario site of the Breast Cancer Family Registry. |
Q23924183 | Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33 |
Q114184688 | Incorporating progesterone receptor expression into the PREDICT breast prognostic model |
Q34250215 | Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations |
Q35443535 | Individual and family characteristics associated with protein truncating BRCA1 and BRCA2 mutations in an Ontario population based series from the Cooperative Family Registry for Breast Cancer Studies |
Q35013740 | Influence of perceived breast cancer risk on screening behaviors of female relatives from the Ontario site of the Breast Cancer Family Registry |
Q51776187 | Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study. |
Q37410472 | Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women |
Q35104068 | Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer |
Q38102971 | Insights from mixture cure modeling of molecular markers for prognosis in breast cancer |
Q41392155 | Insulin-like growth factor 1 (IGF-1) receptors, IGF-1, and IGF-2 are expressed in primary human sarcomas. |
Q36742137 | Integrative analyses reveal signaling pathways underlying familial breast cancer susceptibility |
Q45191001 | Invasive lobular carcinoma: to grade or not to grade |
Q34898735 | Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors |
Q39073113 | Involvement and targeted intervention of dysregulated Hedgehog signaling in osteosarcoma |
Q24293651 | Isolation of human cDNAs for asparagine synthetase and expression in Jensen rat sarcoma cells |
Q42521302 | JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer |
Q34392980 | LAF-4 is aberrantly expressed in human breast cancer |
Q57191573 | Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair |
Q28267893 | Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair |
Q29416989 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk |
Q43843244 | Limited influence of germline genetic variation on all-cause mortality in women with early onset breast cancer: evidence from gene-based tests, single-marker regression, and whole-genome prediction |
Q112644625 | Lineage-defined leiomyosarcoma subtypes emerge years before diagnosis and determine patient survival |
Q77556033 | Low levels of expression of an inhibitor of cyclin-dependent kinases (CIP1/WAF1) in primary breast carcinomas with p53 mutations |
Q35119701 | Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium |
Q24315119 | MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma |
Q54044595 | MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. |
Q31043651 | Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. |
Q38463411 | Medical radiation exposure and breast cancer risk: findings from the Breast Cancer Family Registry |
Q35674829 | Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer |
Q92860654 | Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers |
Q114182490 | Mendelian randomisation study of smoking exposure in relation to breast cancer risk |
Q37293236 | Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer |
Q36747465 | Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer |
Q55216953 | Metabolomic profiles in breast cancer:a pilot case-control study in the breast cancer family registry. |
Q72333528 | Metastatic behavior of the RIF-1 murine fibrosarcoma: inhibited by hypophysectomy and partially restored by growth hormone replacement |
Q33915724 | Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens |
Q34497352 | MicroRNA related polymorphisms and breast cancer risk |
Q35207476 | Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes |
Q33718631 | Molecular alterations in bone and soft-tissue sarcoma. |
Q41756370 | Molecular and genetic characterization of human cell lines resistant to L-asparaginase and albizziin |
Q71568948 | Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas |
Q54334754 | Molecular genetic changes in musculoskeletal sarcomas. |
Q48300558 | Molecular structure of the human asparagine synthetase gene |
Q46988962 | Molecular variants of the thiazide-sensitive Na+-Cl- cotransporter in hypertensive families |
Q24658557 | Multigene testing of moderate-risk genes: be mindful of the missense |
Q36897003 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer |
Q71908877 | Multiplex PCR-SSCP for simultaneous screening for mutations in several exons of p53 |
Q73205349 | Mutation in the coding region of the BRCA1 gene leads to aberrant splicing of the transcript |
Q49024646 | Mutational Spectrum in a Worldwide Study of 29,700 Families with BRCA1 or BRCA2 Mutations. |
Q73939659 | Mutational analysis of BRCA1 and BRCA2 genes in Chinese ovarian cancer identifies 6 novel germline mutations |
Q36479856 | New Ontario familial breast cancer registry to facilitate genetic and epidemiologic studies |
Q37356243 | Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. |
Q37237352 | No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study |
Q30374367 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. |
Q37079859 | No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing |
Q44122211 | No increased risk of breast cancer associated with alcohol consumption among carriers of BRCA1 and BRCA2 mutations ages <50 years |
Q37628084 | Non-invasive optical spectroscopic monitoring of breast development during puberty |
Q35752042 | Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures |
Q36696565 | Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations |
Q34398269 | Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations |
Q36280191 | Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers |
Q41545887 | Overexpression of asparagine synthetase in albizziin-resistant murine diploid embryonic stem cells |
Q53400474 | P53 protein accumulation in non-invasive lesions surrounding p53 mutation positive invasive breast cancers. |
Q28584533 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS |
Q47143943 | PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1. |
Q40070779 | Panel sequencing of 264 candidate susceptibility genes and segregation analysis in a cohort of non-BRCA1, non-BRCA2 breast cancer families. |
Q34289136 | Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche |
Q34061135 | Past recreational physical activity, body size, and all-cause mortality following breast cancer diagnosis: results from the Breast Cancer Family Registry |
Q41330027 | Patched-one or smoothened gene mutations are infrequent in chondrosarcoma |
Q112572520 | Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes |
Q35737888 | Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) |
Q37307937 | Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium |
Q39429341 | Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2. |
Q72230768 | Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma |
Q47975546 | Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. |
Q62583133 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes |
Q97524107 | Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants |
Q38342760 | Polymorphisms XRCC1-R399Q and XRCC3-T241M and the risk of breast cancer at the Ontario site of the Breast Cancer Family Registry. |
Q33287624 | Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis |
Q36066735 | Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression |
Q45062920 | Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry |
Q100562109 | Pre-Pubertal Internalizing Symptoms and Timing of Puberty Onset in Girls |
Q37353677 | Prediagnosis reproductive factors and all-cause mortality for women with breast cancer in the breast cancer family registry |
Q36356727 | Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores |
Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
Q47930081 | Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers |
Q42438080 | Prognostic effect of basal-like breast cancers is time dependent: evidence from tissue microarray studies on a lymph node-negative cohort |
Q45235328 | Prognostic factors affecting the natural history of node-negative breast cancer |
Q36629530 | Prognostic microRNAs modulate the RHO adhesion pathway: A potential therapeutic target in undifferentiated pleomorphic sarcomas |
Q42265507 | Protein kinase C epsilon and genetic networks in osteosarcoma metastasis |
Q37149228 | Psychosocial Adjustment in School-age Girls With a Family History of Breast Cancer |
Q33781466 | Pubertal development in girls by breast cancer family history: the LEGACY girls cohort |
Q55508030 | Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. |
Q90242034 | Publisher Correction: Shared heritability and functional enrichment across six solid cancers |
Q33796247 | Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction |
Q36140996 | Quantitative analysis of multidrug resistance gene expression in human osteosarcomas |
Q36512097 | RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies |
Q34540638 | RAD51 and breast cancer susceptibility: no evidence for rare variant association in the Breast Cancer Family Registry study |
Q36009422 | RAD51B in Familial Breast Cancer |
Q100428113 | RNA expression profiling reveals PRAME, a potential immunotherapy target, is frequently expressed in solitary fibrous tumors |
Q114182625 | Rare germline copy number variants (CNVs) and breast cancer risk |
Q28652308 | Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study |
Q28652056 | Rare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancers |
Q28730692 | Rare mutations in XRCC2 increase the risk of breast cancer |
Q35608690 | Rare variants in the ATM gene and risk of breast cancer |
Q37373918 | Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer |
Q28743906 | Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study |
Q60355290 | Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors |
Q90439909 | Recreational Physical Activity Is Associated with Reduced Breast Cancer Risk in Adult Women at High Risk for Breast Cancer: A Cohort Study of Women Selected for Familial and Genetic Risk |
Q40700714 | Reduced growth of human sarcoma xenografts in hosts homozygous for the lit mutation |
Q35155449 | Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia |
Q34321868 | Refined localization of the asparagine synthetase gene (ASNS) to chromosome 7, region q21.3, and characterization of the somatic cell hybrid line 4AF/106/KO15. |
Q43512760 | Regression models, scan statistics and reappearance probabilities to detect regions of association between gene expression and copy number |
Q64101959 | Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study |
Q45951126 | Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. |
Q37632099 | Reproductive risk factors and oestrogen/progesterone receptor-negative breast cancer in the Breast Cancer Family Registry |
Q35750765 | Risk factors for uncommon histologic subtypes of breast cancer using centralized pathology review in the Breast Cancer Family Registry |
Q37085786 | Risk of pancreatic cancer in breast cancer families from the breast cancer family registry |
Q93367394 | Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk |
Q92708085 | Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers |
Q38717239 | Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers |
Q71730149 | SAS is amplified predominantly in surface osteosarcoma |
Q36545934 | SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival |
Q33242109 | SNP-SNP interactions in breast cancer susceptibility |
Q35983751 | Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry |
Q61118451 | Shared heritability and functional enrichment across six solid cancers |
Q64004349 | Shared heritability and functional enrichment across six solid cancers |
Q60613940 | Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer |
Q57591377 | Statistical challenges in high-dimensional molecular and genetic epidemiology |
Q33566957 | TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer |
Q61909878 | TP53Mutations and Outcome in Osteosarcoma: A Prospective, Multicenter Study |
Q37122297 | Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers |
Q57250694 | The AIB1 Polyglutamine Repeat Does Not Modify Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers |
Q44930023 | The APCI1307K allele and breast cancer risk |
Q49817640 | The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity. |
Q24806109 | The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer |
Q44897750 | The CHEK2*1100delC allelic variant and risk of breast cancer: screening results from the Breast Cancer Family Registry |
Q51070817 | The Cooperative Familial Registry for Breast Cancer Studies: design and first year recruitment rates in Ontario. |
Q91178389 | The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer |
Q67517633 | The HER-2/neu oncogene in breast cancer: so what is new? |
Q64116004 | The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With or Mutations |
Q37686870 | The LEGACY Girls Study: Growth and Development in the Context of Breast Cancer Family History |
Q35781316 | The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients |
Q37401496 | The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers |
Q60487433 | The association between weight at birth and breast cancer risk revisited using Mendelian randomisation |
Q64239462 | The association between weight at birth and breast cancer risk revisited using Mendelian randomisation |
Q28240820 | The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis |
Q75216726 | The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer |
Q38835609 | The genomic landscape of epithelioid sarcoma cell lines and tumours |
Q24306302 | The interaction of PP1 with BRCA1 and analysis of their expression in breast tumors |
Q96609076 | The long non-coding RNA NEAT1 promotes sarcoma metastasis by regulating RNA splicing pathways |
Q35476902 | The potential value of sibling controls compared with population controls for association studies of lifestyle-related risk factors: an example from the Breast Cancer Family Registry |
Q35024008 | The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing |
Q36142060 | The role of genetic breast cancer susceptibility variants as prognostic factors |
Q37180708 | Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy |
Q54376091 | Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. |
Q33654997 | Total energy intake and breast cancer risk in sisters: the Breast Cancer Family Registry |
Q89961489 | Transcriptome-wide association study of breast cancer risk by estrogen-receptor status |
Q90370299 | Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival |
Q36544876 | Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry |
Q37003285 | Tumour morphology predicts PALB2 germline mutation status |
Q92994868 | Two truncating variants in FANCC and breast cancer risk |
Q48073212 | Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer |
Q79553555 | Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer |
Q115601277 | Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry |
Q33520568 | Using cancer registry data: agreement in cause-of-death data between the Ontario Cancer Registry and a longitudinal study of breast cancer patients |
Q40346477 | Validation of Intratumoral T-bet+ Lymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer |
Q57306005 | Validation study of thelambdamodel for predicting theBRCA1orBRCA2mutation carrier status of North American Ashkenazi Jewish women |
Q33855441 | Whole-genome amplification enables accurate genotyping for microarray-based high-density single nucleotide polymorphism array |
Q36082470 | Worry is good for breast cancer screening: a study of female relatives from the ontario site of the breast cancer family registry |
Q40238696 | hCDC4 variation in osteosarcoma |
Q74463760 | neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group |
Q45080213 | p185neu is phosphorylated on tyrosine in human primary breast tumors which overexpress neu/erbB-2 |
Q36622414 | p53 missense but not truncation mutations are associated with low levels of p21(CIP1/WAF1) mRNA expression in primary human sarcomas |
Q34083047 | p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance. |
Q74251183 | p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias |
Q37414133 | rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk |
Q40507472 | von Willebrand factor expression in osteosarcoma metastasis |
Search more.